Crisnatol | CAS# 96389-68-3(free base) | experimental anticancer agent

MedKoo Cat#: 413347 | Name: Crisnatol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Crisnatol is an experimental anticancer agent.

Chemical Structure

Crisnatol

CAS#96389-68-3(free base)

Theoretical Analysis

MedKoo Cat#: 413347

Name: Crisnatol

CAS#: 96389-68-3(free base)

Chemical Formula: C23H23NO2

Exact Mass: 345.1729

Molecular Weight: 345.44

Elemental Analysis: C, 79.97; H, 6.71; N, 4.05; O, 9.26

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

96389-68-3(free base) 96389-69-4 (mesylate)

Synonym

Crisnatol; BWA770U; BW-A770U; BW A770U

IUPAC/Chemical Name

1,3-Propanediol, 2-((6-chrysenylmethyl)amino)-2-methyl-

InChi Key

SBRXTSOCZITGQG-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H23NO2/c1-23(14-25,15-26)24-13-17-12-22-18-7-3-2-6-16(18)10-11-21(22)20-9-5-4-8-19(17)20/h2-12,24-26H,13-15H2,1H3

SMILES Code

OCC(C)(NCC1=C2C=CC=CC2=C3C(C4=CC=CC=C4C=C3)=C1)CO

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 345.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Adams DJ. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. Cancer Res. 1989 Dec 1;49(23):6615-20. PMID: 2819712. 2: Villalona-Calero MA, Petit T, Kuhn J, Cobb P, Kraynak M, Eckhardt SG, Drengler R, Simmons C, Santabarbara P, Von Hoff DD, Rowinsky EK. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies. Clin Cancer Res. 1999 Nov;5(11):3369-78. PMID: 10589747. 3: Patel DK, Shockcor JP, Chang SY, Sigel CW, Huber BE. Metabolism of a novel antitumor agent, crisnatol, by a human hepatoma cell line, Hep G2, and hepatic microsomes. Characterization of metabolites. Biochem Pharmacol. 1991 Jul 5;42(2):337-46. doi: 10.1016/0006-2952(91)90721-g. PMID: 1650211. 4: Patel DK, Woolley JL Jr, Shcokcor JP, Johnson RL, Taylor LC, Sigel CW. Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat. Drug Metab Dispos. 1991 Mar-Apr;19(2):491-7. PMID: 1676660. 5: Smalley RV, Goldstein D, Bulkowski D, Hannon C, Buchler D, Knudsen C, Tuttle RL. A phase II study of crisnatol mesylate in patients with ovarian carcinoma. Invest New Drugs. 1992 Jul;10(2):107-12. doi: 10.1007/BF00873127. PMID: 1500264. 6: Harman GS, Craig JB, Kuhn JG, Luther JS, Turner JN, Weiss GR, Tweedy DA, Koeller J, Tuttle RL, Lucas VS, et al. Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule. Cancer Res. 1988 Aug 15;48(16):4706-10. PMID: 3396016. 7: New P, Vokes E, Rogers L, Bazan C, Hohneker J, Eble M, Vilk P. Long-term response to crisnatol mesylate in patients with glioma. Invest New Drugs. 1997;15(4):343-52. doi: 10.1023/a:1005968700694. PMID: 9547677. 8: Poplin EA, Chabot GG, Tuttle RL, Lucas S, Wargin WA, Baker LH. Crisnatol mesylate: phase I dose escalation by extending infusion duration. Invest New Drugs. 1991 Feb;9(1):41-7. doi: 10.1007/BF00194543. PMID: 2026483. 9: Hufford CD, el-Sharkawy SH, Jurgens TM, Mikell JR. Microbial production of a crisnatol metabolite. Pharm Res. 1992 May;9(5):623-5. doi: 10.1023/a:1015893808830. PMID: 1608892. 10: Zucker RM, Adams DJ, Bair KW, Elstein KH. An efficient multiple-exposure analysis of the toxicity of crisnatol, a DNA intercalator in phase II clinical trials. Invest New Drugs. 1992 Apr;10(1):1-15. doi: 10.1007/BF01275471. PMID: 1607248.